This subproject serves as a platform for the design of novel CatSper and Slo3 inhibitors. An AI-guided approach to in silico drug development is pursued, based on homology models of potential inhibitor-binding sites in CatSper and Slo3. New inhibitors are identified through the analysis of known CatSper and Slo3 inhibitors and virtual compound screening. Using high-resolution channel structures, the project will transition towards structure-based drug development. The optimisation of validated inhibitors will employ AI-supported generative design and will be integrated into a design–make–test–analyse cycle. The aim is to develop highly potent and selective CatSper and Slo3 inhibitors.